Immune Tolerance Network (ITN)
69
4
8
42
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 55/100
24.6%
17 terminated/withdrawn out of 69 trials
71.2%
-15.3% vs industry average
1%
1 trials in Phase 3/4
98%
41 of 42 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (69)
Liver Transplantation With Tregs at MGH
Role: collaborator
Brentuximab Vedotin for Systemic Sclerosis
Role: collaborator
Efficacy of Tezepelumab in Peanut Oral Immunotherapy
Role: collaborator
Grass Pollen Immunotherapy Plus Dupilumab for Tolerance Induction
Role: collaborator
Evaluation of AMG 714 for Vitiligo
Role: collaborator
Carfilzomib and Belatacept for Desensitization
Role: collaborator
Daratumumab in Primary Antiphospholipid Syndrome
Role: collaborator
Type 1 Diabetes Extension Study
Role: collaborator
Tolerance by Engaging Antigen During Cellular Homeostasis
Role: collaborator
Belimumab With Rituximab for Primary Membranous Nephropathy
Role: collaborator
CD40L Antagonism in Rheumatoid Arthritis (RA)
Role: collaborator
Daratumumab and Belatacept for Desensitization
Role: collaborator
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
Role: collaborator
Vaginal Microbiome Exposure and Immune Responses in C-section Infants
Role: collaborator
COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 Vaccinations
Role: collaborator
Liver Transplantation With Tregs at UCSF
Role: collaborator
Follow up of LEAP Participants and Their Families
Role: collaborator
Evaluation of Donor Specific Immune Senescence and Exhaustion as Biomarkers of Tolerance Post Liver Transplantation
Role: collaborator
Tregs for the Treatment of Acute Respiratory Distress Syndrome (ARDS) Associated With COVID-19 (regARDS)
Role: collaborator
A Cohort Study of Operationally Tolerant Allograft Recipients
Role: collaborator